CLINICAL STUDIES

SCORED

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

Study Phase:

Phase 3

Criteria:

  • Male or Female 18 years or older
  • Type 2 Diabetes Mellitus (T2DM)
  • HbA1C ≥ 7.0%.
  • History of Cardiovascular and Renal Event
Register